Inventor · disambiguated record
Blythe Sather
Also filed as: SATHER BLYTHE · SATHER BLYTHE D
9 granted patents·13 pending applications·22 citations·filing 2015–2025
82Inventor score
Files withJUNO THERAPEUTICS INC14LYELL IMMUNOPHARMA INC6EDITAS MEDICINE INC1SEATTLE CHILDRENS HOSPITAL1
Top patents by PatentIndex Score
22 records- 0191US11066475B2Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotidesJUNO THERAPEUTICS INC·Filed 2018·Granted Jul 20, 2021·10 cites·23 claims
- 0289US11623961B2Antibodies and chimeric antigen receptors specific for B-cell maturation antigenJUNO THERAPEUTICS INC·Filed 2018·Granted Apr 11, 2023·7 cites·35 claims
- 0389US10786533B2Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2016·Granted Sep 29, 2020·4 cites·24 claims
- 0472US11952408B2HPV-specific binding moleculesJUNO THERAPEUTICS INC·Filed 2018·Granted Apr 9, 2024·1 cites·46 claims
- 0569US2023365699A1Antibodies and chimeric antigen receptors specific for b-cell maturation antigenJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0666US12270032B2Codon-optimized nucleotide sequences encoding an AP-1 transcription factorLYELL IMMUNOPHARMA INC·Filed 2022·Granted Apr 8, 2025·0 cites·20 claims
- 0761US12428486B2Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotidesJUNO THERAPEUTICS INC·Filed 2021·Granted Sep 30, 2025·0 cites·22 claims
- 0861US12144827B2ROR1 targeting chimeric antigen receptorLYELL IMMUNOPHARMA INC·Filed 2022·Granted Nov 19, 2024·0 cites·20 claims
- 0960US2020384031A1Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1055US2025297268A1Codon-optimized nucleotide sequences encoding an ap-1 transcription factorLYELL IMMUNOPHARMA INC·Filed 2025·Application pending·0 cites
- 1151US2023313138A1Methods for culturing cells expressing c-junLYELL IMMUNOPHARMA INC·Filed 2022·Application pending·0 cites
- 1251US2023310605A1Methods for culturing cells expressing ror1-binding proteinLYELL IMMUNOPHARMA INC·Filed 2022·Application pending·0 cites
- 1350US12473345B2Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigenJUNO THERAPEUTICS INC·Filed 2019·Granted Nov 18, 2025·0 cites·37 claims
- 1450US2023398216A1Chimeric activation receptorsLYELL IMMUNOPHARMA INC·Filed 2021·Application pending·0 cites
- 1546US2022184131A1Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methodsJUNO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1646US2021393689A1Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)JUNO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1742US2021015869A1T cells expressing a recombinant receptor, related polynucleotides and methodsJUNO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1842US2021017249A1Methods of producing cells expressing a recombinant receptor and related compositionsJUNO THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1941US2023061455A1Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapyEDITAS MEDICINE INC·Filed 2018·Application pending·0 cites
- 2037US2019136230A1Genetically engineered cells and methods of making the sameJUNO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2133US10494422B2CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodiesSEATTLE CHILDRENS HOSPITAL·Filed 2015·Granted Dec 3, 2019·0 cites·26 claims
- 2232US2018319862A1Chimeric receptors containing traf-inducing domains and related compositions and methodsJUNO THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →